Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hims Hers Health

Exclusive: The COO of Hims & Hers was the third person to try their GLP-1 drugs—and she's ready to share her story

Health executive Melissa Baird is dedicated to breaking the stigma of weight management at work.

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Stock Market Today: Stocks Rise as Fed Speakers Speak and Nvidia Awaits

Markets eked out gains in a low-volume session that was more focused on upcoming earnings from NVDA.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

HIMS Stock Breaks Out On Powerful Turnaround Quarter

HIMS stock sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Stocks Under $5 Insiders Are Aggressively Buying

3 Stocks Under $5 Insiders Are Aggressively Buying

U.S. stocks closed sharply lower, with the Nasdaq Composite dipping around 450 on Thursday. Investors, meanwhile, focused on some notable insider trades.

Hims & Hers Health's Return On Capital Employed Overview

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

Earnings Preview For Hims & Hers Health

Earnings Preview For Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Hims & Hers Health will report an earnings per share (EPS) of $-0.07.

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

1

People

Philip Jefferson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Electronic Arts

First Republic Bank

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

231,413 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play